A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.

Trial Details

NCT ID
NCT06574568
Phase
PHASE1
Sponsor
Excyte Biopharma Ltd
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • YKST02
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Foshan, Guangdong, China|23.02677,113.13148
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures…
  • Diagnosis of multiple myeloma according to the IMWG criteria.
  • Receipt of at least two prior classes of drugs either in separate regimens or as combinations. The three classes are defined as: An immunomodulator…
  • Measurable disease at screening, as defined by at least 1 of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →